U.S. Department of Health & Human Services

NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Formats Text Remove constraint Formats: Text Copyright Public domain Remove constraint Copyright: Public domain Subjects Humans Remove constraint Subjects: Humans Genre Technical Report Remove constraint Genre: Technical Report
Number of results to display per page

Search Results

4. Medicaid managed care: improved oversight needed of payment rates for long-term services and supports : report to Congressional requesters

nlm:nlmuid-101704057-pdf

5. Foster care: HHS has taken steps to support states' oversight of psychotropic medications, but additional assistance could further collaboration : report to Congressional requesters

nlm:nlmuid-101704061-pdf

7. Defense civil support: DOD, HHS, and DHS should use existing coordination mechanisms to improve their pandemic preparedness : report to the Committee on Armed Services, House of Representatives

nlm:nlmuid-101704071-pdf

9. Drug-free community support program: agencies have strengthened collaboration but could enhance grantee compliance and performance monitoring : report to Congressional committees

nlm:nlmuid-101704075-pdf

11. Requirements for transactions with first responders under section 582 of the Federal Food, Drug, and Cosmetic Act--compliance policy

nlm:nlmuid-101704830-pdf

12. Providing regulatory submissions in electronic format--certain human pharmaceutical product applications and related submissions using the eCTD specifications

nlm:nlmuid-101704838-pdf

13. Projecting demand for the services of primary care doctors:

nlm:nlmuid-101708769-pdf

16. Out-of-pocket expenditures for adults with health care expenses for multiple chronic conditions, U.S. civilian noninstitutionalized population, 2014

nlm:nlmuid-101701118-pdf

17. Trends in enrollment, offers, eligibility and take-up for employer-sponsored insurance: private sector, by state Medicaid expansion status, 2008-2015

nlm:nlmuid-101701121-pdf

18. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders

nlm:nlmuid-101712946-pdf

19. Form FDA 3674--certifications to accompany drug, biological product, and device applications/submissions: guidance for sponsors, industry, researchers, investigators, and food and drug administration staff

nlm:nlmuid-101712948-pdf

20. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)

nlm:nlmuid-101712951-pdf

22. IRB waiver or alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects: guidance for sponsors, investigators, and institutional review boards

nlm:nlmuid-101713098-pdf

24. Federal subsidies for health insurance coverage for people under age 65: 2017 to 2027

nlm:nlmuid-101713191-pdf

26. Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance

nlm:nlmuid-101713196-pdf

27. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

nlm:nlmuid-101713206-pdf

29. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713224-pdf

31. Design considerations and pre-market submission recommendations for interoperable medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713256-pdf

32. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713258-pdf

33. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713268-pdf

34. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 1(R1) : residue on ignition/sulphated ash general chapter

nlm:nlmuid-101713272-pdf

35. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 2(R1) : test for extractable volume of parenteral preparations general chapter

nlm:nlmuid-101713277-pdf

36. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 3(R1) : test for particulate contamination : subvisible particles general chapter

nlm:nlmuid-101713281-pdf

37. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4A(R1) : microbiological examination of nonsterile products : microbial enumeration tests general chapter

nlm:nlmuid-101713288-pdf

38. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4B(R1) : microbiological examination of nonsterile products : tests for specified microorganisms general chapter

nlm:nlmuid-101713291-pdf

39. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4C(R1) : microbiological examination of nonsterile products : acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use general chapter

nlm:nlmuid-101713296-pdf

40. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 5(R1) : disintegration test general chapter

nlm:nlmuid-101713299-pdf

41. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 9(R1) : tablet friability general chapter

nlm:nlmuid-101713302-pdf

42. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 10(R1) : polyacrylamide gel electrophoresis general chapter

nlm:nlmuid-101713306-pdf

43. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

nlm:nlmuid-101713330-pdf

44. Workplace safety and health: information on OSHA training for workers on workplace hazards : report to the Chairman, Subcommittee on Health, Employment, Labor, and Pensions, Committee on Education and the Workforce, House of Representatives

nlm:nlmuid-101713337-pdf

46. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

nlm:nlmuid-101713360-pdf

48. Medicare provider education: oversight of efforts to reduce improper billing needs improvement : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713369-pdf

49. Medicaid program integrity: CMS should build on current oversight efforts by further enhancing collaboration with states : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713370-pdf

50. Pediatric trauma centers: availability, outcomes, and federal support related to pediatric trauma care : report to Congressional requesters

nlm:nlmuid-101713371-pdf

51. Veterans' health care: preliminary observations on veterans' access to choice program care : testimony before the Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713373-pdf

53. Veterans health administration: actions needed to better recruit and retain clinical and administrative staff : testimony before the Subcommittee on Health, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713377-pdf

58. Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713411-pdf

59. Emerging infectious diseases: actions needed to ensure improved response to Zika virus disease outbreaks : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713412-pdf

60. Veterans Affairs: improper payment estimates and ongoing efforts for reduction : testimony before the Subcommittee on Oversight and Investigations, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713413-pdf

61. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 8 (R1) : sterility test general chapter

nlm:nlmuid-101713430-pdf

62. Preliminary analysis of legislation that would replace subsidies for health care with block grants

nlm:nlmuid-101713545-pdf

64. Review of access and quality of care in SCHIP using standardized national performance measures

nlm:nlmuid-101322414-pdf

69. The aging services network: accomplishments and challenges in serving a growing elderly population

nlm:nlmuid-101490538-pdf

84. No free lunch?: current challenges facing National School Lunch and School Breakfast Programs

nlm:nlmuid-101527979-pdf

85. The medical education of physicians

nlm:nlmuid-101527983-pdf

89. Community-based long-term care: Wisconsin stays ahead : site visit report

nlm:nlmuid-101477700-pdf

90. Memory supplements: clarifying FDA and FTC roles could strengthen oversight and enhance consumer awareness : report to Congressional requesters

nlm:nlmuid-101726917-pdf

92. Generic drug user fees: application review times declined, but FDA should develop a plan for administering its unobligated user fees : report to the Chairman, Committee on Health, Education, Labor, and Pensions, U.S. Senate

nlm:nlmuid-101726929-pdf

93. Physician workforce: locations and types of graduate training were largely unchanged, and federal efforts may not be sufficient to meet needs : report to Congressional requesters

nlm:nlmuid-101726977-pdf

94. VA information technology: pharmacy system needs additional capabilities for viewing, exchanging, and using data to better serve veterans : report to Congressional committees

nlm:nlmuid-101726978-pdf

96. Hospital value-based purchasing: CMS should take steps to ensure lower quality hospitals do not qualify for bonuses : report to Congressional committees

nlm:nlmuid-101726983-pdf

100. Investigational new drugs: FDA has taken steps to improve the expanded access program but should further clarify how adverse events data are used : report to Congressional addressees

nlm:nlmuid-101727012-pdf